Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence
The objective of this article is to review the contemporary literature on optimal dual antiplatelet therapy (DAPT) duration after drug-eluting stent (DES) implantation. Relevant studies were searched through MEDLINE, the Cochrane database, and the EMBASE database. Of the 6852 publications retrieved,...
Gespeichert in:
| Veröffentlicht in: | European heart journal Jg. 37; H. 4; S. 353 |
|---|---|
| Hauptverfasser: | , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
21.01.2016
|
| Schlagworte: | |
| ISSN: | 1522-9645, 1522-9645 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The objective of this article is to review the contemporary literature on optimal dual antiplatelet therapy (DAPT) duration after drug-eluting stent (DES) implantation. Relevant studies were searched through MEDLINE, the Cochrane database, and the EMBASE database. Of the 6852 publications retrieved, 23 were considered relevant, including 11 randomized controlled trials (RCTs) and 12 meta-analyses. Initially prescribed for 3-6 months after first-generation DES, the recommended duration of DAPT was subsequently prolonged to at least 1 year, a response to reports of late stent thrombosis after DAPT discontinuation. Seven RCTs subsequently suggested that 1-year DAPT may not be necessary after DES implantation, and that a 6-month or even a 3-month course of DAPT may be as effective and safer. In contrast, four RCTs examining the benefit of DAPT beyond 1 year reached conflicting conclusions. In the DAPT trial, 30-month compared with 12-month DAPT after DES resulted in reduced rates of stent thrombosis and major adverse cardiovascular events, but greater rates of major bleeding with increased non-cardiac mortality. Several meta-analyses have subsequently been performed collectively demonstrating increased rates of all-cause mortality with prolonged DAPT compared with shorter DAPT after DES, due to greater non-cardiovascular mortality with prolonged DAPT not offset by a concomitant reduction in cardiac mortality. The benefit-risk ratio of prolonged DAPT appears to be better in patients with myocardial infarction (MI) than in those without prior MI. On the basis of these findings, a personalized approach is advisable when deciding upon the optimal duration of DAPT after DES, wherein the individualized risks of ischaemic vs. bleeding events are carefully considered for each patient. |
|---|---|
| AbstractList | The objective of this article is to review the contemporary literature on optimal dual antiplatelet therapy (DAPT) duration after drug-eluting stent (DES) implantation. Relevant studies were searched through MEDLINE, the Cochrane database, and the EMBASE database. Of the 6852 publications retrieved, 23 were considered relevant, including 11 randomized controlled trials (RCTs) and 12 meta-analyses. Initially prescribed for 3-6 months after first-generation DES, the recommended duration of DAPT was subsequently prolonged to at least 1 year, a response to reports of late stent thrombosis after DAPT discontinuation. Seven RCTs subsequently suggested that 1-year DAPT may not be necessary after DES implantation, and that a 6-month or even a 3-month course of DAPT may be as effective and safer. In contrast, four RCTs examining the benefit of DAPT beyond 1 year reached conflicting conclusions. In the DAPT trial, 30-month compared with 12-month DAPT after DES resulted in reduced rates of stent thrombosis and major adverse cardiovascular events, but greater rates of major bleeding with increased non-cardiac mortality. Several meta-analyses have subsequently been performed collectively demonstrating increased rates of all-cause mortality with prolonged DAPT compared with shorter DAPT after DES, due to greater non-cardiovascular mortality with prolonged DAPT not offset by a concomitant reduction in cardiac mortality. The benefit-risk ratio of prolonged DAPT appears to be better in patients with myocardial infarction (MI) than in those without prior MI. On the basis of these findings, a personalized approach is advisable when deciding upon the optimal duration of DAPT after DES, wherein the individualized risks of ischaemic vs. bleeding events are carefully considered for each patient.The objective of this article is to review the contemporary literature on optimal dual antiplatelet therapy (DAPT) duration after drug-eluting stent (DES) implantation. Relevant studies were searched through MEDLINE, the Cochrane database, and the EMBASE database. Of the 6852 publications retrieved, 23 were considered relevant, including 11 randomized controlled trials (RCTs) and 12 meta-analyses. Initially prescribed for 3-6 months after first-generation DES, the recommended duration of DAPT was subsequently prolonged to at least 1 year, a response to reports of late stent thrombosis after DAPT discontinuation. Seven RCTs subsequently suggested that 1-year DAPT may not be necessary after DES implantation, and that a 6-month or even a 3-month course of DAPT may be as effective and safer. In contrast, four RCTs examining the benefit of DAPT beyond 1 year reached conflicting conclusions. In the DAPT trial, 30-month compared with 12-month DAPT after DES resulted in reduced rates of stent thrombosis and major adverse cardiovascular events, but greater rates of major bleeding with increased non-cardiac mortality. Several meta-analyses have subsequently been performed collectively demonstrating increased rates of all-cause mortality with prolonged DAPT compared with shorter DAPT after DES, due to greater non-cardiovascular mortality with prolonged DAPT not offset by a concomitant reduction in cardiac mortality. The benefit-risk ratio of prolonged DAPT appears to be better in patients with myocardial infarction (MI) than in those without prior MI. On the basis of these findings, a personalized approach is advisable when deciding upon the optimal duration of DAPT after DES, wherein the individualized risks of ischaemic vs. bleeding events are carefully considered for each patient. The objective of this article is to review the contemporary literature on optimal dual antiplatelet therapy (DAPT) duration after drug-eluting stent (DES) implantation. Relevant studies were searched through MEDLINE, the Cochrane database, and the EMBASE database. Of the 6852 publications retrieved, 23 were considered relevant, including 11 randomized controlled trials (RCTs) and 12 meta-analyses. Initially prescribed for 3-6 months after first-generation DES, the recommended duration of DAPT was subsequently prolonged to at least 1 year, a response to reports of late stent thrombosis after DAPT discontinuation. Seven RCTs subsequently suggested that 1-year DAPT may not be necessary after DES implantation, and that a 6-month or even a 3-month course of DAPT may be as effective and safer. In contrast, four RCTs examining the benefit of DAPT beyond 1 year reached conflicting conclusions. In the DAPT trial, 30-month compared with 12-month DAPT after DES resulted in reduced rates of stent thrombosis and major adverse cardiovascular events, but greater rates of major bleeding with increased non-cardiac mortality. Several meta-analyses have subsequently been performed collectively demonstrating increased rates of all-cause mortality with prolonged DAPT compared with shorter DAPT after DES, due to greater non-cardiovascular mortality with prolonged DAPT not offset by a concomitant reduction in cardiac mortality. The benefit-risk ratio of prolonged DAPT appears to be better in patients with myocardial infarction (MI) than in those without prior MI. On the basis of these findings, a personalized approach is advisable when deciding upon the optimal duration of DAPT after DES, wherein the individualized risks of ischaemic vs. bleeding events are carefully considered for each patient. |
| Author | Palmerini, Tullio Stone, Gregg W |
| Author_xml | – sequence: 1 givenname: Tullio surname: Palmerini fullname: Palmerini, Tullio organization: Dipartimento Cardio-Toraco-Vascolare, University of Bologna, Bologna, Italy – sequence: 2 givenname: Gregg W surname: Stone fullname: Stone, Gregg W email: gs2184@columbia.edu, gstone@crf.org organization: Columbia University Medical Center/New York-Presbyterian Hospital, The Cardiovascular Research Foundation, 111 E. 59th Street, 11th Floor, New York, NY 10022, USA gs2184@columbia.edu gstone@crf.org |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26795933$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkElPwzAQRi1URBe4c0I-cgn1kjoJN1SxSZV6gXPlZdymSpxgO5V654fjskic5tPozdPMTNHIdQ4QuqbkjpKKz2HwO5A-7uewOxSUnaEJXTCWVSJfjP7lMZqGsCeElIKKCzRmoqgWFecT9LnuY93KBpvBy1h3Dnc25dSQLtZ9IyM0EHHcgZf9EUsbwWPjh20GzRBrt8Uhgou4bhPr4rfiHuvOaejjSQOH7gQmsZIBDE4BWvDb0ygcagOJvETnVjYBrn7rDL0_Pb4tX7LV-vl1-bDKdE6KmCmgXNEyV1xxzQ1VRpeGEGGt0dRCzmwOFSUgSmbT0YZrWzBVAmWFogwIm6HbH2_vu48BQty0ddDQpM2hG8KGFoJUjBAuEnrziw6qBbPpffqSP27-Pse-AHzxeGA |
| CitedBy_id | crossref_primary_10_1016_j_amjcard_2020_07_033 crossref_primary_10_1093_eurheartj_ehx085 crossref_primary_10_1177_0003319716676721 crossref_primary_10_26599_1671_5411_2023_08_004 crossref_primary_10_1016_j_thromres_2023_08_002 crossref_primary_10_3389_fcvm_2020_586491 crossref_primary_10_3389_fcvm_2022_954704 crossref_primary_10_1016_j_jacc_2017_06_063 crossref_primary_10_3389_fphys_2018_00491 crossref_primary_10_1093_eurheartj_ehx147 crossref_primary_10_1016_j_rccar_2016_09_012 crossref_primary_10_1093_eurheartj_ehx127 crossref_primary_10_1016_j_jacc_2017_02_029 crossref_primary_10_1016_j_pcad_2017_12_004 crossref_primary_10_1093_cvr_cvaa072 crossref_primary_10_1093_eurheartj_ehx503 crossref_primary_10_1016_j_jconrel_2024_06_063 crossref_primary_10_1016_j_rccar_2017_11_017 crossref_primary_10_1161_JAHA_119_012236 crossref_primary_10_1136_bmj_l2222 crossref_primary_10_1161_CIRCINTERVENTIONS_118_007541 crossref_primary_10_1002_jbm_b_33955 crossref_primary_10_1007_s11886_017_0810_9 crossref_primary_10_2217_fca_2017_0017 crossref_primary_10_1007_s12471_017_1023_y crossref_primary_10_1016_j_rec_2018_06_004 crossref_primary_10_1116_1_4953246 crossref_primary_10_1016_j_blre_2016_07_003 crossref_primary_10_1016_j_pec_2021_01_005 crossref_primary_10_2459_JCM_0000000000000434 crossref_primary_10_1002_ccd_70163 crossref_primary_10_1016_j_ijcard_2019_03_030 crossref_primary_10_1093_eurheartj_sux041 crossref_primary_10_1093_ejcts_ezx334 crossref_primary_10_1093_eurheartj_ehw107 crossref_primary_10_1016_j_ahj_2021_12_005 crossref_primary_10_1080_14740338_2019_1680637 crossref_primary_10_1093_eurheartj_ehw627 crossref_primary_10_1093_eurheartj_ehx419 crossref_primary_10_1136_bmjoq_2022_001956 crossref_primary_10_1093_eurheartj_ehv769 crossref_primary_10_1016_j_ijcard_2017_05_119 crossref_primary_10_1016_j_amjcard_2016_03_005 crossref_primary_10_5847_wjem_j_1920_8642_2023_012 crossref_primary_10_1016_j_amjcard_2019_03_024 crossref_primary_10_1002_ccd_26921 crossref_primary_10_1053_j_jvca_2016_10_009 crossref_primary_10_1007_s12928_023_00920_3 |
| ContentType | Journal Article |
| Copyright | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016. For permissions please email: journals.permissions@oup.com. |
| Copyright_xml | – notice: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016. For permissions please email: journals.permissions@oup.com. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/eurheartj/ehv712 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1522-9645 |
| ExternalDocumentID | 26795933 |
| Genre | Journal Article Review |
| GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 08P 0R~ 18M 1TH 29G 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAFWJ AAJKP AAJQQ AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGHP ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCGUY BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD D~K E3Z EBS ECM EE~ EIF EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M41 MHKGH ML0 N9A NGC NOMLY NOYVH NPM NU- NVLIB O9- OAUYM OAWHX OB3 OCZFY ODMLO OGROG OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX ROZ RUSNO RW1 RXO SEL TCURE TEORI TJX W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 7X8 |
| ID | FETCH-LOGICAL-c407t-be13b184b3b3c3d1bdc8d006ffdc1fe42f4e910e682f645d3cf72b8e127b12e02 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 57 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000370975700013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1522-9645 |
| IngestDate | Sun Sep 28 00:07:40 EDT 2025 Mon Jul 21 06:00:55 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Bleeding Dual antiplatelet therapy Stent thrombosis |
| Language | English |
| License | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016. For permissions please email: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c407t-be13b184b3b3c3d1bdc8d006ffdc1fe42f4e910e682f645d3cf72b8e127b12e02 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://academic.oup.com/eurheartj/article-pdf/37/4/353/7112223/ehv712.pdf |
| PMID | 26795933 |
| PQID | 1760920036 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1760920036 pubmed_primary_26795933 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-Jan-21 20160121 |
| PublicationDateYYYYMMDD | 2016-01-21 |
| PublicationDate_xml | – month: 01 year: 2016 text: 2016-Jan-21 day: 21 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | European heart journal |
| PublicationTitleAlternate | Eur Heart J |
| PublicationYear | 2016 |
| SSID | ssj0008616 |
| Score | 2.4412003 |
| SecondaryResourceType | review_article |
| Snippet | The objective of this article is to review the contemporary literature on optimal dual antiplatelet therapy (DAPT) duration after drug-eluting stent (DES)... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 353 |
| SubjectTerms | Drug Administration Schedule Drug Therapy, Combination Drug-Eluting Stents Humans Long-Term Care Meta-Analysis as Topic Myocardial Infarction - therapy Percutaneous Coronary Intervention - methods Platelet Aggregation Inhibitors - administration & dosage Randomized Controlled Trials as Topic Treatment Outcome |
| Title | Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26795933 https://www.proquest.com/docview/1760920036 |
| Volume | 37 |
| WOSCitedRecordID | wos000370975700013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NT9swFLc2mCYuMLYBBYaMxNVqbSdxwgUhRMWFrgeQeqtqv2fWaU1LvyTu_OG8l6TiNGnSLlGkOIn1_LP9_L5-QlyAK7zLEBRwhkxCc1H5kAZlwaUpQogdFyqyCdfr5YNB0W8MbosmrHKzJlYLNUwD28jb2mWdgiOpsqvZs2LWKPauNhQaH8W2JVWGQ7rc4L1aeJ5V1Ke0RRlVZEnauCnpEN_G1ZwZo5e_2_hr7ZiP8m8KZrXRdPf-t4tfxG6jYsrrGhP74gOWX8Xn-8aJ_k28_qRlYkItYFUPv5xGySlZkqQ8nv0h7ZMGU9aZWS-yYhGXMF89KWSYlk-SkFEu5XhCbevMpfJShjr_kT-D6wbPkvdIkHTDachMh0TPahbT7-Kxe_twc6caMgYV6My3VB619XQc9NbbYEF7CDnQlI0Rgo6YmJggqR6Y5SaSqMGG6IzPURvntcGOORBb5bTEIyG53gvoBMzIYQIuKfSoqvET6U8aU9cS5xv5Dgns7MEYlThdLYbvEm6Jw3qQhrO6KsfQZEybbu3xP7x9InZI8alMKUafiu1IUx1_iE9hvRwv5mcViuja69-_AdKn1x8 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimal+duration+of+dual+antiplatelet+therapy+after+drug-eluting+stent+implantation%3A+conceptual+evolution+based+on+emerging+evidence&rft.jtitle=European+heart+journal&rft.au=Palmerini%2C+Tullio&rft.au=Stone%2C+Gregg+W&rft.date=2016-01-21&rft.issn=1522-9645&rft.eissn=1522-9645&rft.volume=37&rft.issue=4&rft.spage=353&rft_id=info:doi/10.1093%2Feurheartj%2Fehv712&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-9645&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-9645&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-9645&client=summon |